Asthma Clinical Research Network (ACRN) Trial - Best Adjustment Strategy for Asthma in Long Term (BASALT)
NCT00495157 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 342
Last updated 2013-04-11
Summary
Asthma can be effectively controlled using inhaled corticosteroid medication. Treatment with inhaled corticosteroids often requires periodic adjustments to medication dosing and frequency levels. This study examines whether it is more beneficial to adjust corticosteroid treatment based on asthma symptoms and/or biomarkers of lung function versus standard medical guidelines.
Conditions
Interventions
- BEHAVIORAL
-
Symptom-based adjustment
Symptom-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
- BEHAVIORAL
-
Biomarker-based adjustment
Biomarker-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
- BEHAVIORAL
-
Guideline-based adjustment
Guideline-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
Sponsors & Collaborators
-
National Heart, Lung, and Blood Institute (NHLBI)
collaborator NIH -
Milton S. Hershey Medical Center
lead OTHER
Principal Investigators
-
William J. Calhoun, MD · University of Texas, Galveston
-
Mario Castro, MD · Washington University School of Medicine
-
Robert F. Lemanske, MD · University of Wisconsin, Madison
-
Richard J. Martin, MD · National Jewish Health
-
Elliot Israel, MD · Brigham and Women's Hospital
-
Stephen P. Peters, MD, PhD · Wake Forest University Health Sciences
-
Homer A. Boushey, MD · University of California, San Francsico
-
Stephen I. Wasserman, MD · University of California, San Diego
-
Emily DiMango, MD · Columbia University
-
Monica Kraft, MD · Duke University
-
Reuben M. Cherniack, MD · National Jewish Health
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-06-30
- Primary Completion
- 2010-07-31
- Completion
- 2010-07-31
Countries
- United States
Study Locations
More Related Trials
-
Comparison of Two Medication Adherence Strategies to Improve Asthma Treatment Adherence
NCT00115323 ·Status: COMPLETED ·Phase: NA
-
Real Life Effectiveness in Patients With Not Optimally Controlled Asthma
NCT00784953 ·Status: COMPLETED
-
As Needed Beclomethasone/Salbutamol Combination in Single Inhaler for Mild Persistent Asthma
NCT00382889 ·Status: COMPLETED ·Phase: PHASE3
-
Alendronate to Prevent Loss of Bronchoprotection in Asthma
NCT02230332 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma
NCT04503460 ·Status: UNKNOWN ·Phase: PHASE4
-
One Month Dose Response Study of AZD1981 in Asthma Patients Uncontrolled on Inhaled Steroids
NCT00758589 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Efficacy of Inhaled Corticosteroid (ICS) Therapy in Moderate-Severe Bronchial Asthma
NCT00411567 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Using the Blood Eosinophil Count to Guide Systemic Corticosteroid Treatment in Asthma Exacerbations
NCT05417906 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy
NCT01397162 ·Status: TERMINATED ·Phase: PHASE2
-
Markers of Airway Inflammation in BAL Fluid From Children With Asthma
NCT00838552 ·Status: COMPLETED
-
A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma
NCT01823016 ·Status: COMPLETED ·Phase: PHASE2
-
Down-titration of Steroids in Patients With Difficult Asthma With no Bronchial Hyperreactivity
NCT03321877 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma
NCT00528723 ·Status: COMPLETED ·Phase: PHASE3
-
Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers
NCT05111262 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®
NCT00532922 ·Status: COMPLETED
-
Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy
NCT02502890 ·Status: COMPLETED
-
Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes
NCT00521222 ·Status: COMPLETED ·Phase: NA
-
Zileuton and Exhaled Nitric Oxide in Asthmatics
NCT00575861 ·Status: COMPLETED ·Phase: PHASE4
-
Long-acting Beta Agonist Step Down Study
NCT01437995 ·Status: COMPLETED ·Phase: PHASE4
-
A 6 Months NIS to Evaluate the Use of Rescue Medication and Quality of Life in Adult Asthmatic Subjects Treated With Symbicort® SMART®
NCT00884689 ·Status: COMPLETED
-
Study In Asthma Control
NCT00273026 ·Status: TERMINATED ·Phase: PHASE4
-
REPLACE: Can Exercise Replace Inhaled Corticosteroid Treatment in Asthma? A RCT
NCT03290898 ·Status: COMPLETED ·Phase: NA
-
Mechanisms of Acute Asthma Exacerbations Through Molecular Analysis of Airway Secretions and Tissues
NCT00603629 ·Status: COMPLETED
-
Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma
NCT07326995 ·Status: RECRUITING ·Phase: PHASE2
-
Improving the Quality of Care for Asthma Patients at Risk of Exacerbations
NCT06596512 ·Status: NOT_YET_RECRUITING ·Phase: NA